Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating

Viking Therapeutics, Inc. (NASDAQ:VKTX) ranks among the best short squeeze stocks to buy right now. On November 20, H.C. Wainwright retained its Buy rating and $102 price target for Viking Therapeutics, Inc. (NASDAQ:VKTX) following the end of enrollment in the company’s VANQUISH-1 obesity trial.

The trial, which enrolled around 4,650 individuals, concluded ahead of schedule and will compare three different doses to a placebo over a 78-week period. VANQUISH-2, the company’s second trial, which aims to enroll around 1,100 people with type 2 diabetes who happen to be obese or overweight, is still enrolling and is expected to be completed in the first quarter of 2026.

Viking Therapeutics, Inc. (NASDAQ:VKTX) also released exploratory analysis data from its Phase 2 VENTURE trial at ObesityWeek 2025 on November 6, demonstrating significant improvements in cardiometabolic measures among obese patients. Notably, 78% of prediabetic individuals who received VK2735 had normal glycemic control after 13 weeks, as opposed to 29% in the placebo group.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing treatments for metabolic and endocrine disorders, including obesity, NASH, and rare diseases like X-linked adrenoleukodystrophy (X-ALD).

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.